Background:  BPNT1 is a member of the magnesium-dependent, lithium-sensitive phosphomonoesterase superfamily. Using magnesium as a cofactor, BPNT1 catalyzes the conversion of PAPS (adenosine 3’-phosphate 5’ phosphosulfate) to APS (adenosine 5’-phosphosulfate) and the conversion of PAP (3’(2’)-phosphoadenosine 5’ phosphate) to AMP (adenosine 5’-phosphate). Expressed ubiquitously with highest levels in brain and kidney, BPNT1 is potently inhibited by lithium, a drug used for the treatment of manic depression and bipolar affective disorder, suggesting a possible role for BPNT1 in the etiology of mood disorders. Inhibition of BPNT1 leads to an accumulation of PAP and subsequent inhibition of sulfotransferases which may result in changes in gene expression, changes in phosphatidylinositol second messenger function and/or changes in sulfation processes.

Description: Rabbit polyclonal to BPNT1

Immunogen: KLH conjugated synthetic peptide derived from BPNT1

Specificity:  ·Reacts with Human, Mouse and Rat.

·Isotype: IgG

Application:  ·Western blotting: 1/100-500. Predicted Mol wt: 33 kDa;

·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;

·Immunocytochemistry/Immunofluorescence: 1/100;

·Immunoprecipitation: 1/50;

·ELISA: 1/500;

·Optimal working dilutions must be determined by the end user.